RMC-5127
Phase 1Small molecule
Revolution MedicinesRMC-5127 is one of 28 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Non-Small Cell Lung Cancer (NSCLC)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
DATROWAY
Daiichi SankyoPhase 3
Paraplatin
AAvyxa
Phase 3
Alimta
GGynecologic Oncology Group
Phase 3
Taxotere
AAvyxa
Phase 3
Tylenol
KKenvue Brands
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Pumitamig
Bristol-Myers SquibbPhase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RMC-5127. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company